Cite
HARVARD Citation
Attwell, S. et al. (n.d.). The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies. European journal of cancer. pp. S88-. [Online].